Added to YB: 2025-11-27
Pitch date: 2025-11-25
TEVA [neutral]
Teva Pharmaceutical Industries Limited
+15.7%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$30.7B
Pitch Price
$82.89
Price Target
31.00 (-68%)
Dividend
N/A
EV/EBITDA
9.65
P/E
43.30
EV/Sales
2.72
Sector
Pharmaceuticals
Category
growth
Teva’s pivot continues - highlights from Jeffries Healthcare conference
TEVA (update): Pivoting from generics to novel pharma via Duvakitug (anti-TL1a antibody) for IBD. Positive Phase 2b data, Phase 3 H2 2025. Expanding to 2 new indications (likely systemic sclerosis + AD/asthma). 50/50 Sanofi partnership caps upside but de-risks trials. Behind Merck's tulisokibart. $31 PT 12mo on pipeline revaluation.
Read full article (3 min)